| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.0 | 1.0 |
| Net income | -25.2 | -10.1 |
| EPS (diluted, $ a share) | $-0.14 | $-0.14 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: STTK. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Shattuck Labs, Inc.: key numbers
- Share price
- $4.66Close, Nov 16
- Market cap
- $475M
- Shares outstanding
- 101.84MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Shattuck Labs, Inc.
All →Shattuck Labs Financial Results
Shattuck Labs reported financial results for the third quarter of 2026, highlighting the initiation of the RECEPTIVE-CD1 Phase 2b trial for SL-325 in Crohn’s disease. The company also announced plans to start a Phase 2 trial in hidradenitis suppurativa and reported a cash position of $115.3 million, providing a runway into 2028.
“We are very excited to begin Phase 2 clinical development with SL-325 in both Crohn’s disease and hidradenitis suppurativa. We believe these two studies will allow direct comparisons with the TL1A antibody class and evaluate the efficacy that may be left on the table due to the potential immunogenicity liabilities of TL1A antibodies.”
Taylor Schreiber, M.D., Ph.D., Chief Executive Officer